


09-05 (2)

1645  
RECEIVED  
SEP 09 2002  
TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATE


"Express Mail" Label No. : EV 032 110 020 US  
Serial No. : 10/091,019  
Applicant(s) : Robert B. Harris et al.  
Filing Date : March 5, 2002  
Title: : METHOD FOR HIGH LEVEL INSECT EXPRESSION  
OF RAGE PROTEINS  
Examiner : Unassigned  
Group Art Unit : 1645  
Type of Document(s) : Transmittal Form  
Information Disclosure Statement (in duplicate)  
PTO/SB/08A (7 pages)  
References: 101  
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

 (signature)  
Madge Leonard

Date of Deposit 9-4-02

41305-270555  
WINLIB01:957086.1



plus sign (+) inside this box →



EV 032 110 020 US PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Total Number of Items in This Submission (including Transmittal Form)	106
Attorney Docket Number	41305-270555 (2001-01)

### ENCLOSURES (check all that apply)

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment / Response<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br>(in duplicate)<br><input type="checkbox"/> Certified Copy of Priority<br>Document(s)<br><input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application<br><input type="checkbox"/> Response to Missing<br>Parts under 37 CFR<br>1.52 or 1.53 | <input type="checkbox"/> Assignment Papers<br>(for an Application)<br><input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to<br>Group<br><input type="checkbox"/> Appeal Communication to Board of<br>Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group<br>(Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s)<br>(please identify below):<br>Express Mail Certificate –<br>EV 032 110 020 US<br>PTO/SB/08A (7 pages)<br>References: 101<br>Return Postcard |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Cynthia B. Rothschild, Esq. Reg. No. 47,040
Signature	
Date	9/4/02

### CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service's first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	SENT VIA EXPRESS MAIL		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WINLIB01:881070.1

RECEIVED  
SEP 11 2002  
TECH CENTER 1600/2900



TP2001-01

EV 032 110 020 US

PATENT

SEP 09 2002  
FBI CENTER 1600/2000

RECEIVED



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Robert B. Harris et al.  
 Serial No. : 10/091,019  
 Filing Date : March 5, 2002  
 Title : HIGH LEVEL INSECT EXPRESSION OF RAGE PROTEIN  
 Examiner : Unassigned  
 Group Art Unit : 1645

Assistant Commissioner of Patents  
 Washington, DC 20231

Sir:


## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO/SB/08A. A copy of each of the 101 references listed on the attached form is submitted herewith. In submitting the attached references for consideration, Applicants do not waive any rights to appropriate action to establish patentability over the listed documents should they be applied as references against the claims of the present application. This Information Disclosure Statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made.

It is respectfully requested that the references listed on the attached form be expressly considered by the Examiner and be made of record in the application and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first action on the merits in the present application. Accordingly, it is believed that no fees are due for consideration of this Information Disclosure Statement. However, should any fees be due, the Assistant Commissioner is authorized to charge such fees to Deposit Account 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

  
 Cynthia B. Rothschild, Reg. No. 47,040

Date: 9/4/02

KILPATRICK STOCKTON LLP  
 1001 West Fourth Street  
 Winston-Salem, North Carolina 27101-2400  
 (336) 747-7541 Phone  
 (336) 607-7500 Facsimile  
**Attorney Docket No.: 41305-270555**  
 41305-270555WINLIB01:957087.1

RECEIVED  
SEP 14 2002

PTO/SB/O8A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SEP 8 4 2002  
U.S. PATENT & TRADEMARK OFFICE

CANCELLED

Please type a plus sign (+) inside this box → ☐

Substitute for form 1449APTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 7

## Complete if Known

Application Number 10/091,019  
Filing Date March 5, 2002  
First Name of Inventor Robert B. Harris  
Group Art Unit 1645  
Examiner Name Unassigned  
Attorney Docket Number 41305-270555 (2001-01)  
Express Mail Certificate EV 032 110 020 US


20	WO	99/18987		Trustees of Columbia Univ. NYC	04-22-99	✓
21	WO	99/31257		Stichting Inst. Voor Dierhouderij en Diergezondheid et al.	06-24-99	✓
22	WO	99/51721		KANG et al.	10-14-99	✓
23	WO	99/54485		Trustees of Columbia Univ. NYC	10-28-99	✓
24	WO	00/20458		Trustees of Columbia Univ. NYC	04-12-00	✓
25	WO	00/20621		Trustees of Columbia Univ. NYC	04-13-00	✓

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 7

## **Complete if Known**

Application Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	41305-270555
Express Mail Certificate	EV 032 110 020 US

TECHNICAL 1500/2900  
SEP 04 2002

+ RECEIVED

## **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	26	BRADFORD, M. A., <i>Anal. Biochem.</i> , <b>72</b> , 248-254, 1976	✓
	27	CHAZENBALK et al., Expression of the Extracellular Domain of the Thyrotropin Receptor in the Baculovirus System Using a Promoter Active Earlier than the Polyhedrin Promoter, <i>J. Biol. Chem.</i> , <b>270</b> , 1543-1549, 1995	✓
	28	CHEN, L. et al., Coexpression of Cytochrome p450s and Human NADPH-P450 Oxidoreductase in the Baculovirus System, <i>Drug Metabolism and Disposition</i> , <b>25/4</b> , 399-405, 1997 (XP002074128)	✓
	29	CHITALEY et al., Antagonism of Rho-Kinase Stimulates Rat Penile Erection via Nitric Oxid-Independent Pathway, <i>Nature Medicine</i> , Jan. <b>7(1)</b> , 119-122, 2001	✓
	30	CLONTECH MANUAL, <i>www.clontech.com and Palo Alto, CA</i>	✓
	31	CRALL et al., The Extramural and Intramural Coronary Arteries in Juvenile Diabetes Mellitus, <i>Am. J. Med.</i> , <b>64</b> , 221-230, 1978	✓
	32	DEGENHARDT et al., Chemical Modification of Proteins by Methylglyoxal, <i>Cell Mol. Biol.</i> , <b>44</b> , 1139-1145, 1998	✓
	33	DYER et al., Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose, <i>J. Biol. Chem.</i> , <b>266</b> , 11654-11660, 1991	✓
	34	DYER et al., Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging, <i>J. Clin. Invest.</i> , <b>91</b> , 2463-2469, 1993	✓
	35	HAMBY et al., Reappraisal of the Role of the Diabetic State in Coronary Artery Disease, <i>Chest</i> , <b>2</b> , 251-257, 1976	✓
	36	HAMMES et al., Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product Ne-(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations, <i>Diabetologia</i> , <b>42</b> , 603-607, 1999	✓
	37	HOFMANN et al., RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides, <i>Cell</i> , <b>97</b> , 889-901, 1999	✓
	38	HORI et al., The Receptor for Advanced Glycation End Products (RAGE) is a Cellular Binding Site for Amphotericin, <i>J. Biol. Chem.</i> , <b>270</b> , 25752-25761, 1995	✓
	39	HSU et al., Effects of Co-expressing Chaperone BiP on Functional Antibody Production in the Baculovirus System, <i>Prot. Expr. Purif.</i> , <b>5</b> , 595-603, 1994	✓
	40	HULST, M. M. et al., Glycoprotein E1 of Hog Cholera Virus Expressed in Insect Cells Protects Swine from Hog Cholera, <i>Journal of Virology</i> , <b>67/9</b> , 5435-5442, 1993	✓
	41	HULST, M. M. et al., Glycoprotein E2 of Classical Swine Fever Virus: Expression in Insect Cells and Identification as a Ribonuclease, <i>Virology</i> , <b>200</b> , 558-565, 1994	✓
	42	HUTTUNEN et al., Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling	✓

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 7

## **Complete if Known**

Applicant Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	41305-270555
Express Mail Certificate	EV 032 110 020 US

		Pathways, <i>J. Biol. Chem.</i> , <b>274</b> , 19919-24, 1999	
43	JARVIS, <i>Insect Cell Culture Engineering</i> , Macel Dekker, Inc., New York, NY, 1993, Cover Pages, Table of Contents, Chapters 1, 2, 3, 5, 7, and 8		
44	JOHNSON et al., Antioxidant with Marked Lipid- and Glucose-Lowering Activity in Diabetic Rats and Mice, <i>Diabetes</i> , <b>42</b> , 1179, 1993	✓	
45	KANNEL et al., Diabetes and Cardiovascular Disease: The Framingham Study" <i>J. Am. Med. Assoc.</i> , <b>241</b> , 2035-2038, 1979	✓	
46	KANNEL et al., Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study, <i>Diab. Care</i> , <b>2</b> , 120-126, 1979	✓	
47	KING, G. et al., Assessment of Virus Production and CAT Expression by Insect Cells in Serum-Free and Serum-Supplemented Media Using a Temperature Sensitive Baculovirus, <i>Biotechnology &amp; Bioengineering</i> , <b>38</b> , 1091-1099, 1991	✓	
48	KISLINGER et al., N <sup>ε</sup> -(Carboxymethyl)Lysine Adducts of Proteins are Ligands for receptor for Advanced Glycation End Products that Activate cell Signaling Pathways and Modulate Gene Expression, <i>J. Biol. Chem.</i> , <b>274</b> , 31740-31749, 1999	✓	
49	KITTS et al., A Method for Producing Recombinant Baculovirus Expression Vectors at High Frequency, <i>Biotechniques</i> , <b>14</b> , 810-817, 1993	✓	
50	KUMAR et al., Rage at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloid $\beta_{1-40}$ Peptide, <i>Neurosci. Program</i> , P141-#275.19, 2000	✓	
51	KWEON, C. et al., Expression of Envelope Protein (E2) of Bovine Viral Diarrhea Virus in Insect Cells, <i>J. Vet. Med. Sci.</i> , <b>59/5</b> , 415-419, 1997	✓	
52	LEDER et al., v-Ha-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic-acid, <i>Proc. Natl. Acad. Sci.</i> , <b>87</b> , 9178-9182, 1990	✓	
53	LI et al., Control of Expression, Glycosylation, and Secretion of HIV-1 gp120 by Homologous and Heterologous Signal Sequences, <i>Virology</i> , <b>204</b> , 266-278, 1994	✓	
54	LI et al., Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products, <i>J. Biol. Chem.</i> , <b>272</b> , 16498-16506, 1997	✓	
55	LI et al., Sp1-Binding Elements in the Promoter of RAGE Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells, <i>J. Biol. Chem.</i> , <b>273</b> , 30870-30878, 1998	✓	
56	LUCKOW, Trends in the Development of Baculovirus Expression Vectors, <i>BioTechnology</i> , <b>6</b> , 47-55, 1991	✓	
57	LUGERING et al., The Myeloic Related Protein MRP8/14 (27E10 Antigen) - Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function, <i>Eur. J. Clin. Invest.</i> , <b>25</b> , 659-664, 1995	✓	
58	MIYATA et al., $\beta_2$ -Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis, <i>J. Clin. Invest.</i> , <b>92</b> , 1243-1252, 1993	✓	
59	MIYATA et al., The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE- $\beta_2$ Microglobulin with Human	✓	

+ RECEIVED

TECH CENTER 1600/2600  
SEP 6 2002

O I P E  
CANCELED  
SEP 04 2002  
PATENT & TRADEMARK

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 5 of 7

Complete if Known	
Application Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	41305-270555
Express Mail Certificate	EV 032 110 020 US


		Mononuclear Phagocytes Via an Oxidant-sensitive Pathway, <i>J. Clin. Invest.</i> , <b>98</b> , 1088-1094, 1996	
60		MOSER, C. et al., Detection of Antibodies against CSFV in Swine Sera by Indirect ELISA Using Recombinant Envelope Glycoprotein 32, <i>Veterinary Microbiology</i> , <b>51</b> , 41-53, 1996	✓
61		NEEDLEMAN et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, <i>J. Mol. Biol.</i> , <b>48</b> , 443, 1970	✓
62		NEEPER et al., Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins, <i>J. Biol. Chem.</i> , <b>267</b> , 14998-15004, 1992	✓
63		NGUYEN, B. et al., Fed-Batch Culture of Insect Cells: A Method to Increase the Yield of rhNGF in the Baculovirus Expression System, <i>Journal of Biotechnology</i> , <b>31</b> , 205-217, 1993 (XP002074131)	✓
64		PARK et al., Suppression of Accelerated Diabetic Atherosclerosis by the Soluble Receptor for Advanced Glycation Endproducts, <i>Nature Med.</i> , <b>4</b> , 1025-1031, 1998	✓
65		PARKIKINEN et al., Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides, <i>J. Biol. Chem.</i> , <b>268</b> , 19726-19738, 1993	✓
66		PEARSON et al., Improved Tools for Biological Sequence Comparison, <i>Proc. Natl. Acad. Sci. USA</i> , <b>85</b> , 2444-2448, 1998	✓
67		PETRIC, M. et al., Baculovirus expression of Pestivirus Non-Structural Proteins, <i>Journal of General Virology</i> , <b>73</b> , 1867-1871, 1992	✓
68		POSSEE et al., Nucleotide Sequence of the <i>Autographa californica</i> Nuclear Polyhedrosis 9.4 kbp EcoRI-I and -R (Polyhedrin Gene) Region, <i>Virology</i> , <b>185</b> , 229-241, 1991	✓
69		PYORALA et al., Diabetes and Atherosclerosis: an Epidemiologic View, <i>Diab. Metab. Rev.</i> , <b>3</b> , 463-524, 1987	✓
70		RADFORD, K. M. et al., The Indirect Effects of Multiplicity of Infection on Baculovirus Expressed Proteins in Insect Cells: Secreted and Non-Secreted Products, <i>Cytotechnology</i> , <b>24</b> , 73-81, 1997	✓
71		RAMMES et al., Myeloid-Related Protein (MRP) 8 and MRP14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway, <i>J. Biol. Chem.</i> , <b>272</b> , 9496-9502, 1997	✓
72		RAUVALA et al., Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons, <i>J. Biol. Chem.</i> , <b>262</b> , 16625-16635, 1987	✓
73		REDDY et al., Nε-(Carboxymethyl)Lysine Is a Dominant Advanced Glycation End Product (RAGE) Antigen in Tissue Proteins, <i>Biochem.</i> , <b>34</b> , 10872-10878, 1995	✓
74		REDDY, J. R. et al., Application of Recombinant Bovine Viral Diarrhea Virus Proteins in the Diagnosis of Bovine Viral Diarrhea Infection of Cattle, <i>Veterinary Microbiology</i> , <b>51</b> , 119-133, 1997	✓
75		RITTHALER, U. et al., Expression of Receptors for Advanced Glycation End Products in Peripheral Occlusive Vascular Disease, <i>Am. J. of Pathology</i> , <b>146/3</b> , 688-694, 1995	✓

+ RECEIVED

RECEIVED  
SEP 4 2002  
TECH CENTER 1600/2000







Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0951-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 7

## **Complete if Known**

Application Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	41305-270555
Express Mail Certificate	EV 032 110 020 US

SEP 04 2002

SEP 04 2002

RECEIVED

76	ROBERTSON et al., Atherosclerosis in Persons with Hypertension and Diabetes Mellitus, <i>Lab Invest.</i> , <b>18</b> , 538-551, 1968	✓
77	RUGGLI, N. et al., Baculovirus Expression and Affinity Purification of Protein E2 of CSFV Strain Alfort/187, <i>Virus Genes</i> , <b>10/2</b> , 115-126, 1995	✓
78	SCHAFER et al., The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology, <i>TIBS</i> , <b>21</b> , 134-140, 1996	✓
79	SCHLEICHER et al., Increased Accumulation of the Glycoxidation Product Nε-(Carboxymethyl)Lysine in Human Tissues in Diabetes and Aging, <i>J. Clin. Invest.</i> , <b>99 (3)</b> , 457-468, 1997	✓
80	SCHMIDT et al., Isolation and Characterization of Two Binding Proteins for Advanced Glycosylation End Products from Bovine Lung Which Are Present on the Endothelial Cell Surface, <i>J. Biol. Chem.</i> , <b>267</b> , 14987-14997, 1992	✓
81	SCHMIDT et al., The Dark Side of Glucose, <i>Nature Med.</i> , <b>1</b> , 1002-1004, 1995	✓
82	SCHMIDT et al., The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications, <i>Circ. (Suppl.)</i> , <b>96</b> , #194, 1997	✓
83	SMITH et al., Comparison of Biosequences, <i>Adv. Appl. Math.</i> , <b>2</b> , 482-89, 1981	✓
84	TAGUCHI et al., Blockade of RAGE – Amphoterin Signaling Suppresses Tumour Growth and Metastases, <i>Nature</i> , <b>405</b> , 354-357, 2000	✓
85	TANAKA et al., The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-kB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells, <i>J. Biol. Chem.</i> , <b>275</b> , 25781-25790, 2000	✓
86	TEILLET et al., Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats, <i>J. Am. Soc. Nephrol.</i> , <b>11</b> , 1488-1497, 2000	✓
87	VAN RIJN, P. A. et al., Classical Swine Fever Virus (CSFV) Envelope Glycoprotein E2 Containing One Structural Antigenic Unit Protects Pigs from Lethal CSFV Challenge, <i>Journal of General Virology</i> , <b>77</b> , 2737-2745, 1996	✓
88	VAUGHN et al., The Establishment of Two Cell Lines from the Insect Spodoptera Frugiperda (Lepidoptera; Noctuidae) <i>In Vitro</i> , <b>13</b> , 213-217, 1977	✓
89	VLASSARA et al., Advanced Glycation End-products and Atherosclerosis, <i>The Finnish Medical Society DUODECIM, Ann. Med.</i> , <b>28</b> , 419-426, 1996	✓
90	WALLER et al., Status of the coronary Arteries at Necropsy in Diabetes Mellitus with Onset after Age 30 Years, <i>Am. J. Med.</i> , <b>69</b> , 498-506, 1980	✓
91	WAUTER, et al., Advanced Glycation End Products (AGEs) on the Surface of Diabetic Erythrocytes Bind to the Vessel Wall Via a Specific Receptor Inducing Oxidant Stress in the Vasculature: A Link between Surface-Associated AGEs and Diabetic Complications, <i>Proc. Natl. Acad. Sci. USA</i> , <b>91</b> , 7742-7746, 1994	✓
92	WAUTIER et al., Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy: Soluble Receptor for Advanced Glycation End	✓

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

**Complete if Known**

Application Number	10/091,019
Filing Date	March 5, 2002
First Named Inventor	Robert B. Harris
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	41305-270555
Express Mail Certificate	EV 032 110 020 US

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 7

		Products Blocks Hyperpermeability in Diabetic Rats, <i>J. Clin. Invest.</i> , <b>97</b> , 238-243, 1995	
	93	WAUTIER et al., Diabetic Vasculopathy: Central Role of Oxidant Stress in Diabetic Vascular Hyperpermeability, <i>Sup. 1, Circulation</i> , <b>92</b> :1-230, article 1093	✓
	94	WISCONSIN GENETICS SOFTWARE PACKAGE RELEASE 7.0, <i>Genetics Computer Group</i> , 575 Science Drive, Madison, WI, Electronic Handouts	✓
	95	WU, J. et al., Recombinant Protein Production in Insect Cell Cultures Infected with a Temperature Sensitive Baculovirus, <i>Cytotechnology</i> , <b>9</b> , 141-147, 1992	✓
	96	YAN et al., Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation End Products with Their Receptors/Binding Proteins, <i>J. Biol. Chem.</i> , <b>269</b> , 9889-9887, 1994	✓
	97	YAN et al., RAGE and Amyloid- $\beta$ Peptide Neurotoxicity in Alzheimer's Disease, <i>Nature</i> , <b>382</b> , 685-691, 1996	✓
	98	YAN et al., An Intracellular Protein That Binds Amyloid- $\beta$ Peptide and Mediates Neurotoxicity in Alzheimer's Disease, <i>Nature</i> , <b>389</b> , 689-695, 1997	✓
	99	YAN et al., Amyloid- $\beta$ Peptide-Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease, <i>Proc. Natl. Acad. Sci. USA</i> , <b>94</b> , 5296-5301, 1997	✓
	100	YAN et al., Receptor-Dependent Cell Stress and Amyloid Accumulation in Systemic Amyloidosis, <i>Nat. Med.</i> , <b>6</b> , 643-651, 2000	✓
	101	ZIMMER et al., The S100 Protein Family: History, Function, and Expression, <i>Brain Res. Bull.</i> , <b>37</b> , 417-429, 1995	✓

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

41305-270555  
WINLIB01:949882.1

+ RECEIVED  
SEP 10 2002  
SEP 10 2002  
SEP 10 2002

